omni bio pharmaceutical inc (OMBP) Key Developments
Omni Bio Pharmaceutical, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:15 PM
Sep 10 14
Omni Bio Pharmaceutical, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 03:15 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Bruce E. Schneider, Chairman and Chief Executive Officer.
Omni Bio Pharmaceutical, Inc. Appoints Jack Riccardi as Chief Financial Officer, with Effective from September 1, 2014
Aug 14 14
Omni Bio Pharmaceutical, Inc. announced the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014. Prior to his role at Green Street Ventures, Mr. Riccardi served as Chief Financial Officer, Treasurer and Secretary of ADial Pharmaceuticals, where he oversaw the commercialization effort, drug market studies, and advanced valuation analyses for several late stage pharmacotherapies. He also served as Chief Financial Officer of Modern Visuals, a software start-up venture spun off from Siemens Technology Group, where he successfully prepared the company for its eventual sale to a strategic buyer. Mr. Riccardi spent eight years at General Motors, last serving as Director, Strategic Planning. While at GM, Jack initiated content acquisition and strategic alliance efforts expanding GM's OnStar brand into new household markets, established the company's corporate technology venture fund for direct investment into promising technologies, and founded the company's Business Development Forum.
Omni Bio Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt
Jun 16 14
Omni Bio Pharmaceutical, Inc. filed its 10-K on Jun 16, 2014 for the period ending Mar 31, 2014. In this report its auditor, Hein & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Omni Bio Pharmaceutical, Inc. Appoints Bruce D. Forrest as Chief Development Officer
May 1 14
Omni Bio Pharmaceutical, Inc. announced the appointment of Dr. Bruce D. Forrest to the position of Chief Development Officer. Dr. Forrest is currently President of B D Forrest & Company, Inc. Dr. Forrest has been retained over the past 18 months by Omni Bio to assist the company with such services. In his expanded role of Chief Development Officer he will now also oversee implementation of the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule that is being targeted for the treatment of Type 1 diabetes, graft versus host disease and various inflammatory conditions, including chronic gout. Included in this role will be interface and leadership responsibilities for work being performed by recently engaged cell line optimization and product manufacturing partner, Gallus BioPharmaceuticals, Inc. Dr. Forrest has over 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. Dr. Forrest was previously Senior Vice President in Vaccines R&D at Wyeth Pharmaceuticals where he was responsible for clinical and development activities for all late phase programs.
Omni Bio Pharmaceutical, Inc. Announces Publication of Its Pilot Study of Alpha-1 Antitrypsin in Type 1 Diabetes
Apr 30 14
Omni Bio Pharmaceutical, Inc. announced the publication of final results from its pilot study of AAT in patients with recent onset Type 1 diabetes (T1D) in the Journal of Clinical Endocrinology and Metabolism. The study, which was conducted under the leadership of Dr. Peter Gottlieb at the Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, concluded that AAT may have a beneficial effect on T1D in recently diagnosed patients through the down-modulation of IL-1 and other pro-inflammatory cytokines in the blood cells of treated patients. IL-1b is known to be harmful to insulin-producing cells and plays a role in T1D. The authors further concluded that targeting inflammation with inhibitors of the innate immune system, such as AAT, might represent an efficient therapeutic strategy for disease prevention. Twelve patients with recently diagnosed T1D were enrolled in the study with each receiving 8 consecutive weekly infusions of 80 mg/kg of AAT. Patients were evaluated for effects of therapy on C-peptide levels following a mixed meal glucose tolerance test as a measure of insulin-producing islet cell function, and on proinflammatory cytokine measures of innate immunity over an 18 month period post-dosing. Key findings were as follows: AAT led to increased or unchanged levels of C-peptide responses in four patients during 18 months' follow up; the total content of TLR4-induced cellular IL-1 in monocytes at 12 months among all patients was reduced 3-fold compared to baseline (p < 0.05); Monocyte production of IL-1 was reduced from 82% at baseline to 42% at 12 months; Similar reductions were seen using TLR7/8 and TLR3 agonists in monocytes and myeloid dendritic cells (mDCs); Unexpectedly, the reduction in cellular IL-1 was observed at 9-12 months post-treatment but not in a cohort of untreated diabetics; Improved islet cell function in the four responder patients correlated with the reduced monocytes and mDC production levels of IL-1 (p < 0.04 and p < 0.02, respectively); No significant adverse effects were reported in the study.